Clinical trials: ES-SCLC
Lung Cancer
Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
The purpose of this study is to test the safety of study drug LDE225 at different dose levels. The investigators will be testing three different dose levels and the dose will depend on when the patients enters the study and which…
- Trial name
- NCT01579929
- Testing
- LDE225, Etoposide and Cisplatin
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Extensive Stage Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with Anlotinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve extensive…
- Trial name
- NCT05896059
- Testing
- Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
Small Cell Lung Cancer
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the…
- Trial name
- NCT04924101
- Testing
- Pembrolizumab, MK-4830, Boserolimab
- Where
- 49 sites in United States, Austria and 9 more
- Volunteers
- 122 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06769971
- Testing
- Ivonescimab, Cadonilimab, Etoposide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University
Extensive-stage Small-cell Lung Cancer
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not…
- Trial name
- NCT07459634
- Testing
- Lurbinectedin, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jazz Pharmaceuticals
Extensive Stage Lung Small Cell Carcinoma
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
This phase II trial studies whether atezolizumab in combination with talazoparib works better than atezolizumab alone as maintenance therapy for patients with SLFN11-positive extensive-stage small cell lung cancer.
- Trial name
- NCT04334941
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 561 sites in United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Extensive-stage Small-cell Lung Cancer
First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy
This is an open-label, single arm Phase II study designed to observe and evaluate the efficacy and safety of sequential thoracic radiotherapy in the first-line treatment of extensive small cell lung cancer with chemotherapy…
- Trial name
- NCT06586697
- Testing
- Thoracic Radiotherapy
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Henan Cancer Hospital
Extensive-stage Small Cell Lung Cancer
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
This study is a one arm, open, single center phase II study. The main purpose of this study was to evaluate the tolerance and preliminary efficacy of SHR1316 combined with chest radiotherapy after induction therapy.
- Trial name
- NCT04562337
- Testing
- SHR1316, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Shandong Cancer Hospital and Institute
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
- Trial name
- DeLLphi-305 (NCT06211036)
- Testing
- Tarlatamab, Durvalumab
- Where
- 219 sites in United States, Argentina and 27 more
- Volunteers
- 563 people
- Sponsor
- Amgen
Small Cell Lung Carcinoma
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Patients with extensive-stage small-cell lung cancer (ES-SCLC) have poor prognosis, with limited treatment options. Chemo-immunotherapy is the standard 1st-line therapy for patients with ES-SCLC.When 4 cycles of…
- Trial name
- NCT06236997
- Testing
- Adebrelimab, Radiation Therapy, etoposide, carboplatin(EC)
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
Extensive-Stage Small Cell Lung Cancer
Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC
This is a Phase II, single-arm, open-label clinical study to evaluate the efficacy and safety of Sacituzumab Tirumotecan (SKB264) combined with Anlotinib in patients with extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- SKB264-ANLO (NCT07388875)
- Testing
- Sacituzumab Tirumotecan, Anlotinib
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Extensive Stage Small Cell Lung Cancer
Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer
To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with carboplatin and etoposide in the treatment of extensive-stage small cell lung cancer.
- Trial name
- NCT04346914
- Testing
- recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lee's Pharmaceutical Limited
Small-cell Lung Cancer
Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC
This single-arm, Phase II, multicenter study was designed to evaluate the safety and efficacy of Camrelizumab (anti-programmed death-receptor 1 [PD-1] antibody) in combination with Apatinib+carboplatin plus (+) etoposide in…
- Trial name
- NCT04683198
- Testing
- camrelizumab, Apatinib Mesylate, Carboplatin
- Volunteers
- 69 people
- Sponsor
- Chinese Academy of Medical Sciences
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Iadademstat + SBRT With Atezo in ES-SCLC
This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor…
- Trial name
- TIARA (NCT07113691)
- Testing
- Iadademstat, Atezolizumab, SBRT
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University
Extensive-stage Small-cell Lung Cancer
A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC
This is a randomized, Phase III, multicenter, double-blinded, placebo-controlled study designed to evaluate the safety and efficacy of ZKAB001 in combination with carboplatin + etoposide compared with treatment with placebo +…
- Trial name
- NCT04878016
- Testing
- ZKAB001, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Lee's Pharmaceutical Limited
Extensive-stage Small-cell Lung Cancer
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
To evaluate the tolerability and safety of Low-dose radiotherapy combined with concurrent Chemotherapy, Toripalimab and Tifcemalimab in first-line treatment of Extensive-Stage Small Cell Lung Cancer, and to determine the RP2D.
- Trial name
- NCT06732258
- Testing
- Low-dose radiotherapy, Tifcemalimab injection, Toripalimab
- Sponsor
- Sichuan University
Small Cell Lung Cancer Extensive Stage
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
This clinical trial will evaluate the combination of quaratusugene ozeplasmid with atezolizumab as maintenance therapy for patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).
- Trial name
- Acclaim-3 (NCT05703971)
- Testing
- quaratusugene ozeplasmid, atezolizumab
- Where
- 17 sites in United States
- Volunteers
- 62 people
- Sponsor
- Genprex, Inc.
Small Cell Lung Carcinoma
FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction
Cyclic, 5-day calorie restriction is a safe metabolic intervention when combined with standard therapies in cancer patients, favorably reshaping peripheral blood and intratumor metabolism and immunity in a way that may improve…
- Trial name
- FASTIMMUNE (NCT05703997)
- Testing
- Cyclic, 5-day calorie restriction, Atezolizumab
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Extensive-stage Small Cell Lung Cancer
Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer
This is a single-arm Phase Ib/II multicenter open-label study, with translational sub-study, of atezolizumab plus autologous dendritic cell vaccine as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- VENEZO-LUNG (NCT04487756)
- Testing
- Atezolizumab 1200 mg in 20 ML Injection, ADC Vaccine, Carboplatin
- Where
- 3 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Instituto Oncológico Dr Rosell
Extensive Stage Lung Small Cell Cancer
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
This phase II trial compares the effect of adding radiation therapy to the usual maintenance therapy with Serplulimab versus Serplulimab alone in patients who have already received Serplulimab plus chemotherapy for the treatment…
- Trial name
- NCT06350162
- Testing
- Serplulimab, Chest Radiation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital